Renal fibrosis pathway

The term "Renal fibrosis pathway" encompasses the diverse molecular signaling cascades that drive the formation and deposition of fibrotic tissue within the kidney, leading to loss of function and chronic kidney disease. It does not refer to a single, discrete molecular target or receptor; rather, it describes a group of molecular and cellular signaling pathways involved in the process leading to renal (kidney) fibrosis. Key canonical pathways include the transforming growth factor-beta (TGF-β)/Smad signaling axis (TGF-β/Smad3 in particular), Wnt/β-catenin pathway, ECM (extracellular matrix) protein signaling (collagens, fibronectin, tenascin-C), connective tissue growth factor (CTGF), hypoxia-inducible factors (HIFs), and inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β). These act together to reprogram resident renal cells (notably tubular epithelial cells, fibroblasts, and pericytes) toward a profibrotic phenotype, promoting ECM protein deposition, EMT, inflammation, and ultimately scarring. Therapeutic research has focused not on "the pathway" as a unified target, but on specific effectors within these signaling networks—especially TGF-β1 (and its downstream mediator Smad3), mineralocorticoid receptor, SGLT2, and HIFs. Drugs such as antisense oligonucleotides, small molecule inhibitors (e.g., HIF-prolyl hydroxylase inhibitors for anemia, mineralocorticoid receptor antagonists), and natural compounds such as leonurine (targeting TGF-β/Smad3 and NF-κB) have been evaluated for their anti-fibrotic efficacy. However, none is directed at a single "renal fibrosis pathway" protein or receptor; rather, they target specific components or nodes within this complex network. Key points: - There is no canonical molecule or receptor named "Renal fibrosis pathway"; the phrase refers collectively to multiple interacting signaling pathways. - The term encompasses a disease process, not a uniquely druggable molecular target. - Major molecular targets within the pathway include TGF-β1 (transforming growth factor beta 1), Smad3, Wnt/β-catenin, CTGF, HIF-1α, and mineralocorticoid receptor. - Any further structured annotation should be mapped to specific molecules (e.g., "Transforming growth factor beta 1 receptor", "Smad3") rather than the undifferentiated "renal fibrosis pathway".

Other names

Renal fibrogenesis pathwayKidney fibrosis signaling

Not applicable to the pathway itself; mechanism of action applies to individual components and their targeted drugs.